首页 > 最新文献

Hepato-gastroenterology最新文献

英文 中文
Regulatory mechanisms of transcription factors and target genes on gastric cancer by bioinformatics method. 用生物信息学方法研究转录因子和靶基因对胃癌的调控机制。
Pub Date : 2015-03-01
Tao Jian, Yun Chen

Background/aims: Gastric cancer is one of the most lethal diseases and has caused a global health problem. We aimed to elucidate the major mechanisms involved in the gastric cancer progression.

Methodology: The expression profile GSE13911 was downloaded from GEO database, composing of 31 normal and 38 tumor samples. The transcription factor (TF)--target gene regulatory network and protein-protein interaction (PPI) network related to gastric cancer were obtained from TRED and TRANSFAC databases. After combining the two networks, we constructed an integrated network.

Results: In total, 5255 DEGs in tumor samples were identified, which were mainly enriched in 12 pathways including cell cycle. The integrated network of TF--target gene--protein interaction included 7 genes related to cell cycle, in which E2F1 was predicted to mediate the expression of MCM4, MCM5 and CDC6 through regulating the expression of its target gene MCM3.

Conclusion: In gastric cancer progression, E2F1 may play vital roles in the involvement of cell cycle pathway through regulating its target gene MCM3, which might interact with MCM4, MCM5 and MCM7. Besides, STAT1 was another potentially critical transcription factor which could regulate multiple target genes.

背景/目的:胃癌是最致命的疾病之一,已成为全球性的健康问题。我们的目的是阐明参与胃癌进展的主要机制。方法:从GEO数据库下载表达谱GSE13911,由31个正常样本和38个肿瘤样本组成。从trred和TRANSFAC数据库中获得与胃癌相关的转录因子(TF)-靶基因调控网络和蛋白-蛋白相互作用(PPI)网络。将两个网络结合起来,我们构建了一个集成网络。结果:在肿瘤样本中共鉴定出5255个deg,主要富集于细胞周期等12条通路。TF-靶基因-蛋白相互作用的整合网络包括7个与细胞周期相关的基因,其中E2F1通过调控其靶基因MCM3的表达介导MCM4、MCM5和CDC6的表达。结论:在胃癌进展过程中,E2F1可能通过调控其靶基因MCM3参与细胞周期通路,并可能与MCM4、MCM5、MCM7相互作用。此外,STAT1是另一个潜在的关键转录因子,可以调节多个靶基因。
{"title":"Regulatory mechanisms of transcription factors and target genes on gastric cancer by bioinformatics method.","authors":"Tao Jian,&nbsp;Yun Chen","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>Gastric cancer is one of the most lethal diseases and has caused a global health problem. We aimed to elucidate the major mechanisms involved in the gastric cancer progression.</p><p><strong>Methodology: </strong>The expression profile GSE13911 was downloaded from GEO database, composing of 31 normal and 38 tumor samples. The transcription factor (TF)--target gene regulatory network and protein-protein interaction (PPI) network related to gastric cancer were obtained from TRED and TRANSFAC databases. After combining the two networks, we constructed an integrated network.</p><p><strong>Results: </strong>In total, 5255 DEGs in tumor samples were identified, which were mainly enriched in 12 pathways including cell cycle. The integrated network of TF--target gene--protein interaction included 7 genes related to cell cycle, in which E2F1 was predicted to mediate the expression of MCM4, MCM5 and CDC6 through regulating the expression of its target gene MCM3.</p><p><strong>Conclusion: </strong>In gastric cancer progression, E2F1 may play vital roles in the involvement of cell cycle pathway through regulating its target gene MCM3, which might interact with MCM4, MCM5 and MCM7. Besides, STAT1 was another potentially critical transcription factor which could regulate multiple target genes.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 138","pages":"524-8"},"PeriodicalIF":0.0,"publicationDate":"2015-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33253615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical implication of peritoneal cytology in the pancreatic cancer patients who underwent curative resection followed by adjuvant gemcitabine or S-1 chemotherapy. 胰腺癌患者行根治性切除后辅助吉西他滨或S-1化疗腹膜细胞学的临床意义。
Pub Date : 2015-01-20 DOI: 10.1200/JCO.2015.33.3_SUPPL.252
T. Aoyama, Yusuke Katayama, M. Murakawa, M. Shiozawa, M. Morimoto, N. Yamamoto, T. Yoshikawa, Y. Rino, M. Masuda, S. Morinaga
BACKGROUND/AIMSThe clinical implications of peritoneal lavage cytology (CY) status in the patients who received curative resection and adjuvant chemotherapy have not been established.METHODOLOGYWe retrospectively analyzed clinical data from 143 consecutive patients who underwent macroscopically curative resection and received adjuvant gemcitabine or S-1 chemotherapy for pancreatic cancer from 2005 to 2014 in our institution. Correlations between CY status and survival and clinicopathological features were investigated.RESULTSOf the 143 patients, 21 patients were peritoneal washing cytology positive (CY+) (14.7%). Although significant difference was observed in the tumor size, no other correlation between cytology status and clinicopathological parameter existed. The recurrence free survival (RFS) rates at 3 and 5 years after surgery were 5.1% and 0% in CY+ patients, respectively, and were 21.5% and 16.1% in peritoneal washing cytology negative (CY-) patients, respectively, which were significantly different (p=0.001). The OS rates at 3 and 5 years after surgery were 17.1% and 8.6% in CY+ patients, respectively, and were 26.1% and 16.1% in CY- patients, respectively, which were trend to worse in the CY+ patients (p=0.254).CONCLUSIONThe patients with CY+ are likely to experience recurrence, even after they received curative resection and adjuvant Gemcitabine or S-1 adjuvant chemotherapy.
背景/目的腹膜灌洗细胞学(CY)状态在接受治愈性切除和辅助化疗的患者中的临床意义尚未确定。方法回顾性分析我院2005年至2014年连续143例胰腺癌患者的临床资料,这些患者接受了宏观治愈性切除并辅助接受吉西他滨或S-1化疗。研究CY状态与生存及临床病理特征的相关性。结果143例患者中,腹膜冲洗细胞学阳性21例(14.7%)。虽然在肿瘤大小上观察到显著差异,但细胞学状态与临床病理参数之间不存在其他相关性。CY+组术后3年和5年无复发生存率(RFS)分别为5.1%和0%,CY-组术后3年和5年无复发生存率分别为21.5%和16.1%,差异有统计学意义(p=0.001)。CY+患者术后3年和5年的OS率分别为17.1%和8.6%,CY-患者术后3年和5年的OS率分别为26.1%和16.1%,CY+患者有加重趋势(p=0.254)。结论CY+患者即使在接受根治性切除和辅助吉西他滨或S-1辅助化疗后仍有复发的可能。
{"title":"Clinical implication of peritoneal cytology in the pancreatic cancer patients who underwent curative resection followed by adjuvant gemcitabine or S-1 chemotherapy.","authors":"T. Aoyama, Yusuke Katayama, M. Murakawa, M. Shiozawa, M. Morimoto, N. Yamamoto, T. Yoshikawa, Y. Rino, M. Masuda, S. Morinaga","doi":"10.1200/JCO.2015.33.3_SUPPL.252","DOIUrl":"https://doi.org/10.1200/JCO.2015.33.3_SUPPL.252","url":null,"abstract":"BACKGROUND/AIMS\u0000The clinical implications of peritoneal lavage cytology (CY) status in the patients who received curative resection and adjuvant chemotherapy have not been established.\u0000\u0000\u0000METHODOLOGY\u0000We retrospectively analyzed clinical data from 143 consecutive patients who underwent macroscopically curative resection and received adjuvant gemcitabine or S-1 chemotherapy for pancreatic cancer from 2005 to 2014 in our institution. Correlations between CY status and survival and clinicopathological features were investigated.\u0000\u0000\u0000RESULTS\u0000Of the 143 patients, 21 patients were peritoneal washing cytology positive (CY+) (14.7%). Although significant difference was observed in the tumor size, no other correlation between cytology status and clinicopathological parameter existed. The recurrence free survival (RFS) rates at 3 and 5 years after surgery were 5.1% and 0% in CY+ patients, respectively, and were 21.5% and 16.1% in peritoneal washing cytology negative (CY-) patients, respectively, which were significantly different (p=0.001). The OS rates at 3 and 5 years after surgery were 17.1% and 8.6% in CY+ patients, respectively, and were 26.1% and 16.1% in CY- patients, respectively, which were trend to worse in the CY+ patients (p=0.254).\u0000\u0000\u0000CONCLUSION\u0000The patients with CY+ are likely to experience recurrence, even after they received curative resection and adjuvant Gemcitabine or S-1 adjuvant chemotherapy.","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"157 1","pages":"200-6"},"PeriodicalIF":0.0,"publicationDate":"2015-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65879553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Living donor right lobe liver transplantation as a treatment for hepatic alveolar echinococcosis: report of three cases. 活体右叶肝移植治疗肝肺泡包虫病3例报告。
Pub Date : 2015-01-01
Tolga Demirbas, Murat Akyildiz, Murat Dayangac, Onur Yaprak, Gulen Dogusoy, Nuray Bassullu, Yildiray Yuzer, Yaman Tokat

Echinococcus alveolaris is a parasite from tenia family which causes tumor-like lesions in the livers of infected people. If it is not diagnosed in the early stage of the disease, it frequently causes multiple cysts in the liver. The clinical importance of the disease is rapid progression, infiltration into different tissues like a malignant tumor and capacity of creating metastatic masses. The disease could be treated either by surgical resection or liver transplantation. The resection of the cystic disease is the preferred treatment method. In cases where resection is not possible, liver transplantation is the choice of treatment. Here we present three cases which were admitted to the hospital with unresectable hepatic alveolar echinococcosis and treated by liver transplantation successfully. Patients for whom surgical resection is not possible, we recommend liver transplantation as the treatment method.

肺泡棘球绦虫是一种来自绦虫科的寄生虫,在感染者的肝脏中引起肿瘤样病变。如果在疾病的早期阶段没有诊断出来,它经常会导致肝脏中的多个囊肿。这种疾病的临床重要性在于进展迅速,像恶性肿瘤一样浸润到不同的组织,并能产生转移性肿块。这种疾病可以通过手术切除或肝移植来治疗。囊性疾病的切除是首选的治疗方法。在切除不可能的情况下,肝移植是治疗的选择。本文报告三例因肝泡包虫病无法切除而入院,经肝移植成功治疗的病例。对于不能手术切除的患者,我们推荐肝移植作为治疗方法。
{"title":"Living donor right lobe liver transplantation as a treatment for hepatic alveolar echinococcosis: report of three cases.","authors":"Tolga Demirbas,&nbsp;Murat Akyildiz,&nbsp;Murat Dayangac,&nbsp;Onur Yaprak,&nbsp;Gulen Dogusoy,&nbsp;Nuray Bassullu,&nbsp;Yildiray Yuzer,&nbsp;Yaman Tokat","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Echinococcus alveolaris is a parasite from tenia family which causes tumor-like lesions in the livers of infected people. If it is not diagnosed in the early stage of the disease, it frequently causes multiple cysts in the liver. The clinical importance of the disease is rapid progression, infiltration into different tissues like a malignant tumor and capacity of creating metastatic masses. The disease could be treated either by surgical resection or liver transplantation. The resection of the cystic disease is the preferred treatment method. In cases where resection is not possible, liver transplantation is the choice of treatment. Here we present three cases which were admitted to the hospital with unresectable hepatic alveolar echinococcosis and treated by liver transplantation successfully. Patients for whom surgical resection is not possible, we recommend liver transplantation as the treatment method.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"93-7"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33125415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A new strategy with a grading system for liver metastases from colorectal cancer. 结直肠癌肝转移分级的新策略
Pub Date : 2015-01-01
Koji Komeda, Michihiro Hayashi, Yoshihiro Inoue, Tetsunosuke Shimizu, Mitsuhiro Asakuma, Fumitoshi Hirokawa, Yoshiharu Miyamoto, Kazuhisa Uchiyama

Background/aims: The optimal indications, including timing, for resection of liver metastases from colorectal cancer (CRCLM) remain controversial. The Japanese Society of Cancer of the Colon and Rectum has proposed "H-classification" based on the maximum size and number of CRCLM, and has advocated the "CRCLM-grade system", which involves adding the presence of primary lymph node metastasis status to H-classification. We evaluated clinicopathological factors in order to elucidate the optimal indications for and timing of hepatectomy.

Methodology: Ninety-six patients who underwent initial hepatectomy for CRCLM between August 1995 and May 2009 were retrospectively analyzed with respect to characteristics of primary colorectal metastatic hepatic tumors, operation details and prognosis.

Results: Multivariate analysis identified depth of invasion in primary colorectal cancer (within sub-serosal (non-se) vs. beyond serosal (se)) and CRCLM-grade as independent risk factors. We then performed analyses using the combination of non-se/se and CRCLM-grade. Kaplan-Meier analysis identified significant differences between non-se+gradeA and se+gradeA, between non-se+gradeB and se+gradeB, and between non-se+gradeC and se+gradeC groups.

Conclusions: We could retrospectively predict survival in CRCLM patients by adopting this new simple classification. This method may allow more precise assessment of operative indications and timing for both operations and perioperative adjuvant treatment.

背景/目的:结肠直肠癌肝转移灶切除术(CRCLM)的最佳适应症(包括时机)仍存在争议。日本结直肠癌协会提出了以CRCLM的最大大小和数量为标准的“h分级”,并主张在h分级中加入原发淋巴结转移状态的“CRCLM分级制”。我们评估了临床病理因素,以阐明肝切除术的最佳适应症和时机。方法:回顾性分析1995年8月至2009年5月96例CRCLM患者行原发性结转移性肝肿瘤的特点、手术细节及预后。结果:多因素分析确定了原发性结直肠癌的浸润深度(在浆膜下(non-se) vs.浆膜外(se))和crclm级别是独立的危险因素。然后,我们使用非se/se和crclm等级的组合进行分析。Kaplan-Meier分析发现,非se+gradeA组与se+gradeA组、非se+gradeB组与se+gradeB组、非se+gradeC组与se+gradeC组之间存在显著差异。结论:我们可以通过采用这种新的简单分类来回顾性预测CRCLM患者的生存。这种方法可以更精确地评估手术指征和手术及围手术期辅助治疗的时机。
{"title":"A new strategy with a grading system for liver metastases from colorectal cancer.","authors":"Koji Komeda,&nbsp;Michihiro Hayashi,&nbsp;Yoshihiro Inoue,&nbsp;Tetsunosuke Shimizu,&nbsp;Mitsuhiro Asakuma,&nbsp;Fumitoshi Hirokawa,&nbsp;Yoshiharu Miyamoto,&nbsp;Kazuhisa Uchiyama","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>The optimal indications, including timing, for resection of liver metastases from colorectal cancer (CRCLM) remain controversial. The Japanese Society of Cancer of the Colon and Rectum has proposed \"H-classification\" based on the maximum size and number of CRCLM, and has advocated the \"CRCLM-grade system\", which involves adding the presence of primary lymph node metastasis status to H-classification. We evaluated clinicopathological factors in order to elucidate the optimal indications for and timing of hepatectomy.</p><p><strong>Methodology: </strong>Ninety-six patients who underwent initial hepatectomy for CRCLM between August 1995 and May 2009 were retrospectively analyzed with respect to characteristics of primary colorectal metastatic hepatic tumors, operation details and prognosis.</p><p><strong>Results: </strong>Multivariate analysis identified depth of invasion in primary colorectal cancer (within sub-serosal (non-se) vs. beyond serosal (se)) and CRCLM-grade as independent risk factors. We then performed analyses using the combination of non-se/se and CRCLM-grade. Kaplan-Meier analysis identified significant differences between non-se+gradeA and se+gradeA, between non-se+gradeB and se+gradeB, and between non-se+gradeC and se+gradeC groups.</p><p><strong>Conclusions: </strong>We could retrospectively predict survival in CRCLM patients by adopting this new simple classification. This method may allow more precise assessment of operative indications and timing for both operations and perioperative adjuvant treatment.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"111-7"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33125419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence and mortality of liver cancer in mainland China: changes in first decade of 21st century. 中国大陆肝癌发病率和死亡率:21世纪第一个十年的变化。
Pub Date : 2015-01-01
Rui Wang, Xin-Zu Chen, Ming-Guang Zhang, Li Tang, Hao Wu

Background/aims: To longitudinally analyze changes of primary liver cancer incidence and mortality in mainland China during the first decade of 21st century.

Methodology: Available data of crude incidence and mortality of primary liver cancer from annual reports of the National Central Cancer Registry in mainland China were retrieved and analyzed.

Results: Either the incidence or mortality of primary liver cancer in mainland China kept increasing and didn't reach peaks during the first decade of the 21st century, particularly among the female population with great incremental rates of incidence (8.76%) and mortality (11.99%) at 2007-2008 and 2009-2010, respectively. The crude incidence increased from 26.18/100,000 persons at 2004 to 29.00/100,000 persons at 2010, while the crude mortality from 25.08/100,000 persons to 28.10/100,000 persons (r=0.857, p=0.014). The incidence and mortality in males kept 2.5-2.9 folds to those in females. The incidence and mortality in rural region were always higher than those in urban regions, but among males both tended to decline in rural region, while in contrast increased in urban region.

Conclusions: Liver cancer still has high incidence and mortality in mainland China, and further effort is required to prevent and control liver cancer, particularly for male and rural population.

背景/目的:对21世纪前10年中国大陆原发性肝癌发病率和死亡率的变化进行纵向分析。方法:检索和分析中国大陆国家癌症中心登记处年度报告中原发性肝癌粗发病率和死亡率的现有数据。结果:21世纪前10年,中国大陆原发性肝癌的发病率和死亡率均呈持续上升趋势,未见高峰,尤其是女性人群,2007-2008年和2009-2010年的发病率和死亡率增幅较大,分别为8.76%和11.99%。粗发病率从2004年的26.18/10万人上升到2010年的29.00/10万人,粗死亡率从25.08/10万人上升到28.10/10万人(r=0.857, p=0.014)。男性的发病率和死亡率是女性的2.5 ~ 2.9倍。农村地区的发病率和死亡率始终高于城市地区,但男性发病率和死亡率在农村地区呈下降趋势,而在城市地区呈上升趋势。结论:肝癌在中国大陆地区仍有较高的发病率和死亡率,需要进一步加强对肝癌的预防和控制,特别是对男性和农村人群。
{"title":"Incidence and mortality of liver cancer in mainland China: changes in first decade of 21st century.","authors":"Rui Wang,&nbsp;Xin-Zu Chen,&nbsp;Ming-Guang Zhang,&nbsp;Li Tang,&nbsp;Hao Wu","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>To longitudinally analyze changes of primary liver cancer incidence and mortality in mainland China during the first decade of 21st century.</p><p><strong>Methodology: </strong>Available data of crude incidence and mortality of primary liver cancer from annual reports of the National Central Cancer Registry in mainland China were retrieved and analyzed.</p><p><strong>Results: </strong>Either the incidence or mortality of primary liver cancer in mainland China kept increasing and didn't reach peaks during the first decade of the 21st century, particularly among the female population with great incremental rates of incidence (8.76%) and mortality (11.99%) at 2007-2008 and 2009-2010, respectively. The crude incidence increased from 26.18/100,000 persons at 2004 to 29.00/100,000 persons at 2010, while the crude mortality from 25.08/100,000 persons to 28.10/100,000 persons (r=0.857, p=0.014). The incidence and mortality in males kept 2.5-2.9 folds to those in females. The incidence and mortality in rural region were always higher than those in urban regions, but among males both tended to decline in rural region, while in contrast increased in urban region.</p><p><strong>Conclusions: </strong>Liver cancer still has high incidence and mortality in mainland China, and further effort is required to prevent and control liver cancer, particularly for male and rural population.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"118-21"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33125420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Conservative treatment and percutaneous catheter drainage improve outcome of necrotizing pancreatitis. 保守治疗和经皮导管引流可改善坏死性胰腺炎的预后。
Pub Date : 2015-01-01
Junjun Sun, Cheng Yang, Weifeng Liu, Yanhui Yang, Shifang Qi, Zhijie Chu, Shiyong Xin, Xiaohui Zhang

Background/aims: To investigate the clinical effects of the maximum conservative treatment algorithm with percutaneous catheter drainage (PCD) as the first choice for necrotizing pancreatitis (NP).

Methodology: Retrospectively analyzed NP patients who had fine needle aspiration (FNA) for proven infection of necrosis which was considered an indication for surgery (n=22, group 1) compared to patients subjected to maximum conservative treatment with PCD in NP patients (n=30, group 2).

Results: On admission, most baseline data did not show any statistical difference between the two groups, In group 2, all patients were implemented maximum conservative treatment, 25 of 30 patients were cured by PCD (83.3%), open necrosectomy were needed for 3 patients (10.0%) and 2 dead during hospitalization (6.7%). Whereas, in group 1, surgical operation rate was 45.6% and hospital mortality 31.8%, both of the ratios differed significantly compared with group 2 (45.6% vs. 10%, P=0.004; 31.8% vs. 6.7%, P=0.046 respectively). Furthemore, Hospital stay were significantly higher in group 1 compared with group 2 (90±18.5 vs. 39±13.4; P=0.033).

Conclusions: A conservative approach with PCD as the first choice to treatment NP might decrease the rate of surgical operation and mortality, and improve the outcome of NP.

背景/目的:探讨经皮导管引流(PCD)作为坏死性胰腺炎(NP)首选的最大保守治疗方案的临床效果。方法:回顾性分析经细针穿刺(FNA)证实有坏死感染的NP患者(n=22,组1)与接受PCD最大保守治疗的NP患者(n=30,组2)的比较。入院时,两组大部分基线数据无统计学差异。2组30例患者均实施最大保守治疗,PCD治愈25例(83.3%),需行开放性坏死切除术3例(10.0%),住院期间死亡2例(6.7%)。组1手术开手术率为45.6%,住院死亡率为31.8%,与组2比较差异有统计学意义(45.6% vs. 10%, P=0.004;31.8% vs. 6.7%, P=0.046)。此外,组1的住院时间明显高于组2(90±18.5∶39±13.4;P = 0.033)。结论:首选PCD保守治疗NP可降低手术率和死亡率,改善NP预后。
{"title":"Conservative treatment and percutaneous catheter drainage improve outcome of necrotizing pancreatitis.","authors":"Junjun Sun,&nbsp;Cheng Yang,&nbsp;Weifeng Liu,&nbsp;Yanhui Yang,&nbsp;Shifang Qi,&nbsp;Zhijie Chu,&nbsp;Shiyong Xin,&nbsp;Xiaohui Zhang","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>To investigate the clinical effects of the maximum conservative treatment algorithm with percutaneous catheter drainage (PCD) as the first choice for necrotizing pancreatitis (NP).</p><p><strong>Methodology: </strong>Retrospectively analyzed NP patients who had fine needle aspiration (FNA) for proven infection of necrosis which was considered an indication for surgery (n=22, group 1) compared to patients subjected to maximum conservative treatment with PCD in NP patients (n=30, group 2).</p><p><strong>Results: </strong>On admission, most baseline data did not show any statistical difference between the two groups, In group 2, all patients were implemented maximum conservative treatment, 25 of 30 patients were cured by PCD (83.3%), open necrosectomy were needed for 3 patients (10.0%) and 2 dead during hospitalization (6.7%). Whereas, in group 1, surgical operation rate was 45.6% and hospital mortality 31.8%, both of the ratios differed significantly compared with group 2 (45.6% vs. 10%, P=0.004; 31.8% vs. 6.7%, P=0.046 respectively). Furthemore, Hospital stay were significantly higher in group 1 compared with group 2 (90±18.5 vs. 39±13.4; P=0.033).</p><p><strong>Conclusions: </strong>A conservative approach with PCD as the first choice to treatment NP might decrease the rate of surgical operation and mortality, and improve the outcome of NP.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"195-9"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33249363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
K-Ras mutation and prognosis of colorectal cancer: a meta-analysis. K-Ras突变与结直肠癌预后的meta分析
Pub Date : 2015-01-01
Yuanyi Rui, Cun Wang, Zongguang Zhou, Xi Zhong, Yongyang Yu

Background/aims: Colorectal cancer (CRC) is one of the most common malignant tumors worldwide. Kirsten ras (K-ras) gene is considered to participate in the progression from adenoma to carcinoma of colorectal neoplasms. The correlation between K-ras mutation and the prognosis of CRC is sill controversial. This study aimed at quantitatively summarizing the evidence for such a relationship.

Methodology: The literature search was based on Pub Med. Population-based and hospital-based case-control studies concerning K-ras mutation and prognosis were eligible for analysis.

Results: 13 literatures were included in the meta-analysis, with 1 multicenter study and 12 case control studies. Totally, 3771 patients were enrolled in the analysis, 1202 of which had K-ras mutation. There were significant difference between the survival of patients with normal and mutated K-ras gene, but no statistic differences were found between either Condon 12 or Condon 13 mutations and prognosis.

Conclusion: Current available evidences demonstrated the K-ras mutation is a predictive molecular mark of colorectal cancer patients' survivals, further studies are needed to investigate the race difference and the relationship between certain K-ras mutation and prognosis.

背景/目的:结直肠癌(CRC)是世界范围内最常见的恶性肿瘤之一。Kirsten ras (K-ras)基因被认为参与了结直肠肿瘤从腺瘤到癌的发展过程。K-ras突变与结直肠癌预后的相关性仍存在争议。本研究旨在定量地总结这种关系的证据。方法:文献检索基于Pub Med。基于人群和基于医院的关于K-ras突变和预后的病例对照研究符合分析条件。结果:13篇文献被纳入meta分析,其中1项多中心研究和12项病例对照研究。共有3771例患者纳入分析,其中1202例患者存在K-ras突变。K-ras基因正常与突变患者的生存率差异有统计学意义,但Condon 12与Condon 13突变与预后无统计学差异。结论:目前已有证据表明K-ras突变是预测结直肠癌患者生存的分子标记,有待进一步研究种族差异及某些K-ras突变与预后的关系。
{"title":"K-Ras mutation and prognosis of colorectal cancer: a meta-analysis.","authors":"Yuanyi Rui,&nbsp;Cun Wang,&nbsp;Zongguang Zhou,&nbsp;Xi Zhong,&nbsp;Yongyang Yu","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>Colorectal cancer (CRC) is one of the most common malignant tumors worldwide. Kirsten ras (K-ras) gene is considered to participate in the progression from adenoma to carcinoma of colorectal neoplasms. The correlation between K-ras mutation and the prognosis of CRC is sill controversial. This study aimed at quantitatively summarizing the evidence for such a relationship.</p><p><strong>Methodology: </strong>The literature search was based on Pub Med. Population-based and hospital-based case-control studies concerning K-ras mutation and prognosis were eligible for analysis.</p><p><strong>Results: </strong>13 literatures were included in the meta-analysis, with 1 multicenter study and 12 case control studies. Totally, 3771 patients were enrolled in the analysis, 1202 of which had K-ras mutation. There were significant difference between the survival of patients with normal and mutated K-ras gene, but no statistic differences were found between either Condon 12 or Condon 13 mutations and prognosis.</p><p><strong>Conclusion: </strong>Current available evidences demonstrated the K-ras mutation is a predictive molecular mark of colorectal cancer patients' survivals, further studies are needed to investigate the race difference and the relationship between certain K-ras mutation and prognosis.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"19-24"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33249641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nutritional management of anastomotic leakage after colorectal cancer surgery using elemental diet jelly. 元素饮食胶对结直肠癌术后吻合口瘘的营养管理。
Pub Date : 2015-01-01
A Ishibe, M Ota, A Kanazawa, J Watanabe, K Tatsumi, K Watanabe, T Godai, S Yamagishi, S Fujii, Y Ichikawa, C Kunisaki, I Endo

Background/aims: Anastomotic leakage is major complication of colorectal surgery. Total parenteral nutrition (TPN) and fasting are conservative treatments for leakage in the absence of peritonitis in Japan. Elemental diet (ED) jelly is a completely digested formula and is easily absorbed without secretion of digestive juices. The purpose of this study was to assess the safety of ED jelly in management of anastomotic leakage.

Methodology: Six hundred and two patients who underwent elective surgery for left side colorectal cancer from January 2008 to December 2011 were included in the study. Pelvic drainage was performed for all patients. Sixty-three (10.5%) patients were diagnosed with an anastomotic leakage, and of these, 31 (5.2%) without diverting stoma were enrolled in this study.

Results: Sixteen patients received TPN (TPN group) and 15 patients received ED jelly (ED group). The duration of intravenous infusion was significantly shorter in the ED group than in the TPN group (15 days versus 25 days, P= 0.008). In the TPN group, catheter infection was occurred in 2 patients who required re-insertion of the catheter.

Conclusion: Conservative management of anastomotic leakage after colorectal surgery with ED jelly appears to be a safe and useful approach.

背景/目的:吻合口瘘是结直肠手术的主要并发症。全肠外营养(TPN)和禁食是保守治疗漏在日本没有腹膜炎。元素饮食(ED)果冻是一种完全消化的配方,很容易吸收,不分泌消化液。本研究的目的是评价ED胶治疗吻合口瘘的安全性。研究方法:2008年1月至2011年12月期间接受左侧结直肠癌择期手术的602例患者纳入研究。所有患者均行盆腔引流。63例(10.5%)患者被诊断为吻合口漏,其中31例(5.2%)患者没有转移造口。结果:16例患者接受TPN治疗(TPN组),15例患者接受ED胶(ED组)。ED组静脉输注时间明显短于TPN组(15天vs 25天,P= 0.008)。在TPN组,2例患者发生导管感染,需要重新插入导管。结论:应用ED胶保守治疗结直肠术后吻合口瘘是一种安全有效的方法。
{"title":"Nutritional management of anastomotic leakage after colorectal cancer surgery using elemental diet jelly.","authors":"A Ishibe,&nbsp;M Ota,&nbsp;A Kanazawa,&nbsp;J Watanabe,&nbsp;K Tatsumi,&nbsp;K Watanabe,&nbsp;T Godai,&nbsp;S Yamagishi,&nbsp;S Fujii,&nbsp;Y Ichikawa,&nbsp;C Kunisaki,&nbsp;I Endo","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>Anastomotic leakage is major complication of colorectal surgery. Total parenteral nutrition (TPN) and fasting are conservative treatments for leakage in the absence of peritonitis in Japan. Elemental diet (ED) jelly is a completely digested formula and is easily absorbed without secretion of digestive juices. The purpose of this study was to assess the safety of ED jelly in management of anastomotic leakage.</p><p><strong>Methodology: </strong>Six hundred and two patients who underwent elective surgery for left side colorectal cancer from January 2008 to December 2011 were included in the study. Pelvic drainage was performed for all patients. Sixty-three (10.5%) patients were diagnosed with an anastomotic leakage, and of these, 31 (5.2%) without diverting stoma were enrolled in this study.</p><p><strong>Results: </strong>Sixteen patients received TPN (TPN group) and 15 patients received ED jelly (ED group). The duration of intravenous infusion was significantly shorter in the ED group than in the TPN group (15 days versus 25 days, P= 0.008). In the TPN group, catheter infection was occurred in 2 patients who required re-insertion of the catheter.</p><p><strong>Conclusion: </strong>Conservative management of anastomotic leakage after colorectal surgery with ED jelly appears to be a safe and useful approach.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"30-3"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33249642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidermal growth factor receptor in CRC patients in the era of the RAS. RAS时代结直肠癌患者表皮生长因子受体的研究。
Pub Date : 2015-01-01
Mustafa Teoman Yanmaz, Gokhan Demir, Sibel Erdamar, Serkan Keskin, Muhammet Fatih Aydin, Sebnem Izmir Guner

The aim of this study was to investigate EGFR expression patterns and the effect of EGFR expression on stage, prognosis and response to conventional chemotherapy agents other than monoclonal antibodies in CRC patients. This study included 59 metastatic CRC patients. The expression of EGFR was quantified by immunochemistry in biopsy specimens that were obtained before treatment was initiated. The cases were considered to be positive for EGFR if >1% of the tumor cells had complete circumferential membranous staining. The median age of the patients was 54.6 years, and 59% of the patients were male. Twenty-six patients presented with stage IV disease, and the remaining patients developed distant metastasis during follow-up. Fifty-one patients were treated with regimens containing irinotecan. The numbers of patients with EGFR expression in the primary tumors, the metastatic lymph nodes and the normal colonic tissue were 34 (65.4%), 10 (76.9%) and 34 (65.4%) respectively. The initial disease stage and lymph node stage were correlated with EGFR expression (p<0.05). Additionally, EGFR positivity was correlated with a statistically significant reduction in the response rate to chemotherapy, the overall survival (21 vs. 28 months) and the progression-free survival (15 vs. 22 months) in metastatic patiens treated with chemotherapy other than targeted therapies. In conclusion, EGFR expression in correlated with stage in all CRC patients and response to chemotherapy and survival in metastatic CRC patients.

本研究的目的是探讨EGFR表达模式以及EGFR表达对结直肠癌患者分期、预后和对单克隆抗体以外常规化疗药物反应的影响。本研究纳入了59例转移性结直肠癌患者。在治疗开始前获得的活检标本中,用免疫化学方法量化EGFR的表达。如果>1%的肿瘤细胞有完整的周膜染色,则认为EGFR阳性。患者中位年龄54.6岁,男性占59%。26例患者出现IV期疾病,其余患者在随访期间发生远处转移。51例患者接受含有伊立替康的方案治疗。在原发肿瘤、转移淋巴结和正常结肠组织中表达EGFR的患者分别为34例(65.4%)、10例(76.9%)和34例(65.4%)。早期疾病分期和淋巴结分期与EGFR表达相关(p
{"title":"Epidermal growth factor receptor in CRC patients in the era of the RAS.","authors":"Mustafa Teoman Yanmaz,&nbsp;Gokhan Demir,&nbsp;Sibel Erdamar,&nbsp;Serkan Keskin,&nbsp;Muhammet Fatih Aydin,&nbsp;Sebnem Izmir Guner","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The aim of this study was to investigate EGFR expression patterns and the effect of EGFR expression on stage, prognosis and response to conventional chemotherapy agents other than monoclonal antibodies in CRC patients. This study included 59 metastatic CRC patients. The expression of EGFR was quantified by immunochemistry in biopsy specimens that were obtained before treatment was initiated. The cases were considered to be positive for EGFR if >1% of the tumor cells had complete circumferential membranous staining. The median age of the patients was 54.6 years, and 59% of the patients were male. Twenty-six patients presented with stage IV disease, and the remaining patients developed distant metastasis during follow-up. Fifty-one patients were treated with regimens containing irinotecan. The numbers of patients with EGFR expression in the primary tumors, the metastatic lymph nodes and the normal colonic tissue were 34 (65.4%), 10 (76.9%) and 34 (65.4%) respectively. The initial disease stage and lymph node stage were correlated with EGFR expression (p<0.05). Additionally, EGFR positivity was correlated with a statistically significant reduction in the response rate to chemotherapy, the overall survival (21 vs. 28 months) and the progression-free survival (15 vs. 22 months) in metastatic patiens treated with chemotherapy other than targeted therapies. In conclusion, EGFR expression in correlated with stage in all CRC patients and response to chemotherapy and survival in metastatic CRC patients.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"40-4"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33249647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Laparoscopic gastrectomy for gastric cancer in China: an overview. 中国腹腔镜胃癌切除术:综述。
Pub Date : 2015-01-01
Huanrong Lan, Naibiao Zhu, Yuefu Lan, Ketao Jin, Lisong Teng

Since its introduction in China in 2000, laparoscopic gastrectomy has shown classical advantages of minimally invasive surgery over open counterpart. Like all the pioneers of the technique, Chinese gastrointestinal surgeons claim that laparoscopic gastrectomy led to faster recovery, shorter hospital stay and more rapid return to daily activities respect to open gastrectomy while offering the same functional and oncological results. There has been booming interest in laparoscopic gastrectomy since 2006 in China. The last decade has witnessed national growth in the application of laparoscopic gastrectomy and yielded a significant amount of scientific data to support its clinical merits and advantages. However, few prospective randomized controlled trials have investigated the benefits of laparoscopic gastrectomy in China. In this article, we make an overview of the current data and state of the art of laparoscopic gastrectomy for gastric cancer in China.

自2000年进入中国以来,腹腔镜胃切除术已显示出微创手术的经典优势。像所有这项技术的先驱一样,中国的胃肠外科医生声称,与开放式胃切除术相比,腹腔镜胃切除术恢复更快,住院时间更短,恢复日常活动更快,同时提供相同的功能和肿瘤结果。自2006年以来,中国对腹腔镜胃切除术的兴趣日益浓厚。在过去的十年中,腹腔镜胃切除术的应用在全国范围内得到了发展,并产生了大量的科学数据来支持其临床优点和优势。然而,在中国,很少有前瞻性随机对照试验调查腹腔镜胃切除术的益处。在这篇文章中,我们对目前中国腹腔镜胃癌切除术的数据和技术进行了综述。
{"title":"Laparoscopic gastrectomy for gastric cancer in China: an overview.","authors":"Huanrong Lan,&nbsp;Naibiao Zhu,&nbsp;Yuefu Lan,&nbsp;Ketao Jin,&nbsp;Lisong Teng","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Since its introduction in China in 2000, laparoscopic gastrectomy has shown classical advantages of minimally invasive surgery over open counterpart. Like all the pioneers of the technique, Chinese gastrointestinal surgeons claim that laparoscopic gastrectomy led to faster recovery, shorter hospital stay and more rapid return to daily activities respect to open gastrectomy while offering the same functional and oncological results. There has been booming interest in laparoscopic gastrectomy since 2006 in China. The last decade has witnessed national growth in the application of laparoscopic gastrectomy and yielded a significant amount of scientific data to support its clinical merits and advantages. However, few prospective randomized controlled trials have investigated the benefits of laparoscopic gastrectomy in China. In this article, we make an overview of the current data and state of the art of laparoscopic gastrectomy for gastric cancer in China.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"234-9"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33251247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Hepato-gastroenterology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1